Varney M D, Palmer C L, Romines W H, Boritzki T, Margosiak S A, Almassy R, Janson C A, Bartlett C, Howland E J, Ferre R
Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.
J Med Chem. 1997 Aug 1;40(16):2502-24. doi: 10.1021/jm9607459.
The design, synthesis, biochemical, and biological evaluation of a novel series of 5-thia-2,6-diamino-4(3H)-oxopyrimidine inhibitors of glycinamide ribonucleotide transformylase (GART) are described. The compounds were designed using the X-ray crystal structure of human GART. The monocyclic 5-thiapyrimidinones were synthesized by coupling an alkyl thiol with 5-bromo-2, 6-diamino-4(3H)-pyrimidinone, 20. The bicyclic compounds were prepared in both racemic and diastereomerically pure forms using two distinct synthetic routes. The compounds were found to have human GART KiS ranging from 30 microM to 2 nM. The compounds inhibited the growth of both L1210 and CCRF-CEM cells in culture with potencies down to the low nanomolar range and were found to be selective for the de novo purine biosynthesis pathway. The most potent inhibitors had 2,5-disubstituted thiophene rings attached to the glutamate moiety. Placement of a methyl substituent at the 4-position of the thiophene ring to give compounds 10, 18, and 19 resulted in inhibitors with significantly decreased mFBP affinity.
描述了一系列新型5-硫杂-2,6-二氨基-4(3H)-氧代嘧啶甘氨酰胺核糖核苷酸转甲酰基酶(GART)抑制剂的设计、合成、生化及生物学评价。这些化合物是利用人GART的X射线晶体结构设计的。通过将烷基硫醇与5-溴-2,6-二氨基-4(3H)-嘧啶酮(20)偶联来合成单环5-硫代嘧啶酮。使用两种不同的合成路线制备了外消旋和非对映体纯形式的双环化合物。发现这些化合物对人GART的Ki值范围为30μM至2 nM。这些化合物在培养中抑制L1210和CCRF-CEM细胞的生长,效力低至低纳摩尔范围,并且发现对从头嘌呤生物合成途径具有选择性。最有效的抑制剂具有连接到谷氨酸部分的2,5-二取代噻吩环。在噻吩环的4-位引入甲基取代基得到化合物10、18和19,导致抑制剂的mFBP亲和力显著降低。